Study summary

Double immunotherapy more than doubled 5-year survival over chemotherapy

CheckMate 743 5-year results · Phase 3, randomized · Published February 2026, Journal of Clinical Oncology

14%alive at 5 years with nivolumab plus ipilimumab, vs 6%

What was tested

Five-year follow-up of nivolumab plus ipilimumab against chemotherapy as first treatment for pleural mesothelioma that cannot be removed by surgery.

What they found

14% were alive at 5 years vs 6% with chemotherapy.
Benefit held across tumor types.
No new safety problems appeared.

What it means

Confirms double immunotherapy as a standard first treatment.

J Clin Oncol, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.